LEXINGTON, Mass., July 21, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, announced today that Dr. Jennifer Buell, President and COO of Agenus, and Dr. Manuel Hidalgo,

LEXINGTON, Mass., June 22, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced that it will make a

- Agenus to receive $35M upfront with $100M in milestones plus royalties - Betta receives exclusive license of balstilimab (anti-PD-1) and zalifrelimab (anti-CTLA-4) in Greater China LEXINGTON, Mass., June 22, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with

LEXINGTON, Mass., June 17, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, announced today that Dr. Jennifer Buell, PhD, President and Chief Operating Officer of Agenus,

LEXINGTON, Mass., June 17, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, announced today that Dr. Walter Flamenbaum, CEO of AgenTus Therapeutics, and Dr. Marc Van

LEXINGTON, Mass., June 16, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infectious diseases, announces that it will host its 2020 Annual Shareholders Meeting virtually due to

- AgenTus allogeneic iNKTs have potential to clear SARS-CoV-2 virus & mitigate harmful inflammation - COVID-19 and cancer clinical trials to commence - Dr. Koen van Besien at Weill Cornell/New York Presbyterian Hospital to lead COVID-19 trials   LEXINGTON, Mass., June 2, 2020 / PRNewswire /

-- No complement mediated toxicities and up to 70% clinical benefit¹ across multiple solid tumors -- Combination of AGEN1181 with Agenus's balstilimab (PD-1) advancing in the clinic -- B. Riley to host conference call with Drs. Steven O'Day and Charles Drake on Next-Generation CTLA-4 agents - June

LEXINGTON, Mass., May 14, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infections, announced today that it will present data on AGEN1181 at the American Society of Clinical

- Cancer and COVID-19 Clinical trials expected to commence soon - Designed for anti-cancer treatment & iNKTs are synergistic with Agenus' checkpoint antibodies - Potential to clear SARS-CoV-2 virus and control harmful inflammation - COVID-19 IND expected to clear shortly LEXINGTON, Mass., May 13,

- AGEN1181 (nextgen CTLA-4) +/- balstilimab (anti-PD-1) shows benefit in 70% of patients in Phase 1 - Balstilimab + Zalifrelimab (anti-CTLA-4) achieve 26% response rates in a cohort of 55 patients with advanced cervical cancer - Two INDs filed for AgenTus cell therapy (Allogeneic iNKTs) for cancer

LEXINGTON, Mass., April 28, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, will release its first quarter 2020 financial results before the market opens on Thursday, May 7, 2020.

LEXINGTON, Mass., April 7, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Agenus Fast Track designation

LEXINGTON, Mass., March 12, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Agenus Fast Track designation

- AGEN1181 +/- balstilimab (anti-PD-1) reveals a complete response and new partial responses in phase 1 clinical trial - Balstilimab & zalifrelimab (anti-CTLA-4) demonstrate 26.5% response rates in an all-comer (non-biomarker selected) population with advanced cervical cancer - FDA grants Fast

$15.1M Milestone from HealthCare Royalty Partners LEXINGTON, Mass., March 10, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, announced the triggering of a $15.1M milestone payment

LEXINGTON, Mass., March 3, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced it will release its fourth quarter and full year 2019 financial results before the market

- Balstilimab and zalifrelimab combination yield >20% response rates - Balstilimab and zalifrelimab combination has best-in-class potential for the treatment of second-line cervical cancer - On track to submit 2 BLAs for these agents in 2020 - Low-dose AGEN1181 monotherapy demonstrated a confirmed

LEXINGTON, Mass., Feb. 6, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced it will hold an Investor Day Thursday, February 20, 2020.

LEXINGTON, Mass., Jan. 9, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, is pleased to announce the appointment of Dr. Jennifer Buell to President and COO.

- AGEN1223 is a novel bi-specific designed to selectively deplete regulatory T cells in the tumor microenvironment - First patient dosed; combinations with other IO agents planned for 2020 LEXINGTON, Mass., Jan. 8, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with

LEXINGTON, Mass., Dec. 19, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1  and cancer vaccines, today announced the first patient dosed with AGEN1181, an anti-CTLA-4 antibody, in

LEXINGTON, Mass., Nov. 12, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1  and cancer vaccines, announced that it will host an R&D Day on November 15, 2019.

- UroGen receives rights to zalifrelimab to be used in its proprietary sustained release formulation for patients with high-grade non-muscle invasive bladder cancer LEXINGTON, Mass., Nov. 11, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of

- PD-1 plus CTLA-4 cervical trial completes planned accrual & planned interim analysis - PD-1 cervical trial on track to complete accrual & planned interim analysis by year-end - Four novel I-O antibodies clear INDs & advance into clinical trials - NexGen CTLA-4 (AGEN1181) advances to 3rd cohort;